{"id":"W2562165295","doi":"10.1182/blood.v108.11.306.306","title":"Clinical Efficacy of Lenalidomide {Revlimid®} in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase II Clinical Trial.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Internal medicine; Fludarabine; Gastroenterology; Rituximab; Rash; Thalidomide; Tumor lysis syndrome; Bendamustine; Chronic lymphocytic leukemia; Pomalidomide; Refractory (planetary science); Progressive disease; Febrile neutropenia; Multiple myeloma; Leukemia; Toxicity; Lymphoma; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00324677,0.0004425388,0.002054958,0.0004118012,0.00006857356,0.00001275482,0.0004854884,0.0006390877,0.0001292187],"category_scores_gemma":[0.004389647,0.0003130321,0.0004629138,0.001074821,0.0008927611,0.0001436015,0.0002488275,0.000849303,0.00002919302],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.01468138,"about_ca_system_score_gemma":0.05589606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001693617,"about_ca_topic_score_gemma":0.0002897211,"domain_scores_codex":[0.9914783,0.0007605851,0.004577635,0.0010368,0.001327713,0.0008189455],"domain_scores_gemma":[0.9937982,0.002281996,0.001357316,0.001675607,0.0005141731,0.0003726845],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9291276,0.04273463,0.008818707,0.0005484775,0.0009292164,0.0007203799,0.0001222263,0.000148791,0.0004671884,0.00002470704,0.00479304,0.01156505],"study_design_scores_gemma":[0.9268704,0.03844366,0.02717964,0.001064802,0.0007820743,0.00003001236,0.00001590233,0.00137761,0.002157858,0.0000094263,0.00174898,0.0003196134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955226,0.0003417835,0.000006694779,0.00003912019,0.0002415439,0.002761384,0.00008237827,0.00007885186,0.0009256636],"genre_scores_gemma":[0.996904,0.000189113,0.0006510432,0.00006113449,0.0005859715,0.00003690161,0.0004269307,0.00009252415,0.001052359],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04121468,"threshold_uncertainty_score":0.9999322,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04379604490781398,"score_gpt":0.3750465100802808,"score_spread":0.3312504651724668,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}